Biotechnology, a specialty sector that lost favor along with technology funds, appears to be making a comeback, judging from a very strong offering by two private-equity biotechnology funds, Reuters reports.

Venture capital firm Abingworth Management of London has raised $350 million for its sixth private-equity biotechnology fund. In June, Schroder Ventures Life Science raised $402 million for its private-equity fund. Undoubtedly, this means better times ahead for biotechnology companies, according to Reuters.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.